epitope-peptide-based HIV vaccine, prokaryotic expression, inclusion body, purification, immunogenicity https://mc06.manuscriptcentral.com/cjm-pubs purified by a three-step process including ion-exchange chromatography and affinity column, and then renatured by stepwise dialysis. Together, the above described procedures generated 43 mg of vaccine protein per liter of fermentation medium, and the final product reached approximately 95% purity. The purified protein was capable of eliciting antigen-specific T cell responses in immunized mice.
Introduction
Human immunodeficiency virus (HIV) 1 is known to have a high mutation rate and sequence diversity (De Groot et al. 2003; van der Kuyl et al. 2012) . It has been difficult to develop a successful HIV vaccine to induce broadly neutralizing antibodies (bNAb) or elicit multifunctional T cells to prevent infection (Mcmichael et al. 2010; Walker et al. 2008) . CD4+ T cells are central to the induction and maintenance of CD8+ T cell and antibody-producing B cell responses, both of which are conceptually essential for protection against the acquisition of HIV infection or the progression of HIV disease McElrath et al. 2008) . Thus how to design a vaccine to induce specific CD4+ T cell responses to HIV is an intensely studied area of HIV vaccine research. Using epitope-based immunogen to stimulate CD4+ T cell responses is one of many new HIV vaccine strategies (Barouch et al. 2013; Fischer et al. 2007; Haynes 2015; Hulot et al. 2015; Korber et al. 2009; Kulkarni et al. 2014; Létourneau et al. 2007; Mothe et al. 2015) .
We have previously designed a peptide-based vaccine (Shu et al. 2014 ) that targets specifically Chinese by first assembling a database that is comprised of 
2009
; Nielsen et al. 2008; Nielsen et al. 2007; Sturniolo et al. 1999; Vita et al. 2010; Walker et al. 2009; Wang et al. 2010 ).
In the present study, an efficient process was developed to produce highly purified recombinant HIV T helper vaccine using an Escherichia coli expression system. The recombinant vaccine was expressed in the form of inclusion bodies that were subsequently purified under denaturing conditions, and then refolded through stepwise dialysis. The final purity of recombinant HIV vaccine protein was approximately 95%, and the quantity of production was 43 mg per liter of fermentation medium, and thus D r a f t primers, respectively. Taq DNA Polymerase (Takara Biotech, Dalian, China) was used for PCR amplification. Purified PCR segments were inserted into pET-30a(+) vector (Novagen, USA) that had been digested with the same restriction enzymes. The recombinant plasmid was used to transform competent E. coli BL21 (DE3) cells (CWbio, Beijing, China).
The positive colonies of transformed E. coli BL21 (DE3) were selected and then cultivated in Luria-Bertani (LB) medium (tryptone 10 g/L, yeast extract 5 g/L, NaCl 10 g/L) supplemented with kanamycin (100 µg/mL) at 37 °C and 200 rpm. When the OD 600 reached 0.4-0.8, the cells were induced with 0.1 mM isopropyl-β-Dthiogalactopyranoside (IPTG) for 12 h at 37 °C. Then, the cultures were centrifuged, and the pellets were processed for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis (Laemmli 1970).
Fed-batch fermentation of recombinant strain
A single cryovial of working culture was inoculated into 30 mL of LB medium with 100 µg/mL kanamycin and grown for 5 h at 37 °C on an orbital shaker (ZQLY-180, Zhichu Instrument, Shanghai, China) at 200 rpm. The culture (10 mL) was transferred into 500 mL flasks containing 100 mL of fermentation media (media composition per L: D r a f t g tryptone, 30 g yeast extract). The pH was maintained at 7.0 with ammonium hydroxide. The flow of inlet air to the fermenter was set at 0.4 L/min. Stirrer speed was set at 300 rpm and temperature was 37 °C. After 3 h of cultivation, when the DO level fell to 50% or below, the stirrer speed was increased in steps of 100 rpm up to maximum of 800 rpm. As the pH began to rise (about 4 h of cultivation), additional feeding media was added with a rate of 0.5 mL/min to hold the pH at 7.0. When the OD 600 reached 15-20, the cells were induced with 0.1 mM IPTG for 12 h at 37 °C. Then, the broth was harvested and centrifuged at 1600 g for 10 min at 4 °C.
Pretreatment of inclusion bodies
The cell pellets obtained from fermentation culture were washed twice in phosphate buffer (Na 2 HPO 4 1.56 g/L, NaH 2 PO 4 0.2 g/L) and resuspended in washing The buffers used in the purification process were all passed through 0.22 µm filter membrane (Millipore, Billerica, USA), and the protein samples collected from each purification step was similarly filtered.
Assay of protein concentration and purity
The concentration of each protein sample was determined using the Bradford method (Bradford 1976 ) (Commassie Blue Staining Kit, Solarbio, Beijing, China).
Especially, to ensure the reliability of results, the samples with 8 M urea or 7 M guranidine-HCl were diluted 5 to 10 fold with PBS. And the concentration was found to be linear in relation to the absorbance reading in spectrophotometer (UV7504, XINMAO, Shanghai, China).
The purity of recombinant protein vaccine was determined by 12% SDS-PAGE.
Gel was stained using 0.1% (w/v) Coomassie brilliant blue R250 for 20 min, then destained using 10% (v/v) methanol with 10% (v/v) acetic acid for 4-12 h. The purity of D r a f t the samples was determined by scanning the processed SDS-PAGE gel and using Gel
Imager (ExCell Bio, Shanghai, China) for analysis.
The final purity of recombinant vaccine was also determined by HPLC with an Agilent 1100 system (Agilent Technologies, USA), equipped with a quarternary pump, thermostat compartment for the column and photodiode array detector. The chromatographic column was Hypersil ODS2 (250 mm×4.6 mm). The HPLC analysis was done at room temperature. A 20 µL aliquot of sample was injected and then eluted with the mobile phase of acetonitrile and 0.1% trifluoroacetic acid (TFA) gradient at an isocratic flow rate of 1 mL/min with a total runtime of 15 min. When 0-10 min, the ratio of acetonitrile with 0.1% TFA increased from 0% to 70%, and fell back to 0% at 14 min. Detection wavelength for protein samples was set at 280 nm.
Western blot analysis
For Western blot analysis, the proteins separated in the SDS-PAGE were transferred to a nitrocellulose membrane (Burnertte 1981), which was then incubated with polyclonal rabbit anti-his antiserum (Santa Cruz, USA) at a 1:500 dilution. After incubation with horseradish-peroxidase-conjugated anti-rabbit IgG (1:2000 dilution),
an ECL Advance Western Blotting Detection Kit (GE, USA) was used for visualization of target protein.
Simple preparation of purified and renatured vaccine protein
The refolded protein vaccine was precooled with 5% mannitol at -40 °C, then lyophilized at -60 °C by vacuum freeze dryer (LGJ-12, SONGYUAN, Beijing, China).
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Assay of host protein and endotoxin in purified protein vaccine
Host protein and endotoxin were determined by following the method as described in Appendix Ⅸ C and Ⅻ E of Part 3 in 2010 edition of Chinese pharmacopeia, respectively.
Immunogenicity assay of recombinant vaccine
Twenty predicted HLA DRB1 class-II restricted HIV-1 epitopes were synthesized by GL Biochem (Shanghai) Ltd. and used in the ELIspot assay. The amino acid sequence of each peptide was described previously (Shu et al. 2014 ).
Male and female Balb/c mice of 6-8 weeks were immunized subcutaneously in the base-of-tail with 100 µL of recombinant vaccine and 2% Alhydrogel adjuvant (Invivogen, USA) mixed at 1:1 ratio. Control mice were immunized with 100 µL of PBS and Alhydrogel mixture. Each mouse received 3 immunizations at weeks 0, 2 and 4. Their spleen cells were then harvested for the ELIspot assay.
ELIspot assay was performed using 96-well-PVDF plates (Millipore, USA) which were coated overnight at 4 °C with 10 µg/ml of primary anti-IFN-γ mAb (Mabtech, Sweden). The antibody coated plates were washed five times with PBS and blocked with RPMI 1640 containing 10% fetal bovine serum (FBS) for 1hr at 37 °C.
Plates were washed 5 times with PBS again. Murine spleen mononuclear cells (MNCs)
were isolated and then treated with ACK lysis buffer to remove RBCs prior to stimulation with peptides. MNC at 3×10 5 cells per well were plated in duplicate wells, and then 2 ng of individual peptides was added to each well. After 30 hours of D r a f t stimulation, plates were washed 5 times. Biotinylated anti-IFN-γ mAb (2 µg/mL) (R46A2) was added to each well and then incubated for 2 h. The plates were then washed 5 times followed by 1 h incubation with Streptavidin-Alkaline Phosphatase (1 µg/mL). The reaction was stopped by adding 100 µL ddH 2 O to each well. The spots were enumerated using CTL ImmunoSpot Software and BioSpot Colony Counting Software.
Results and Discussion
Cloning and expression of the recombinant protein
The target DNA segment was inserted into pET-30a vector and the recombinant plasmid was successfully transformed into E. coli BL21 (DE3) cells. Recombinant plasmid extracted from positive colonies was successfully constructed as confirmed by restriction enzyme digestion ( Fig. 1 ) and DNA sequencing (Fig. 2) .
The transformed E. coli BL21 (DE3) cells were cultivated and induced with 0.1 mM IPTG in LB medium at 37 °C, whereas the control was not induced. The protein profiles of control and induced cells were analyzed on 12% SDS-PAGE. The expression of recombinant target protein was observed with the molecular mass of 39 kDa in induced cell pellets, and absent in controls (Fig. 3A) . As expected, the recombinant protein vaccine was almost exclusively expressed as inclusion bodies. To optimize the conditions for expression of soluble fraction of the recombinant protein D r a f t vaccine, various IPTG concentrations and induction temperatures were assessed.
However, the fraction of target proteins expressed in the form of inclusion bodies was unchanged. Thus 0.1 mM IPTG induction at 37 °C was chosen as the optimal condition for obtaining inclusion bodies. Western blot was carried out with anti-his-tag monoclonal antibody (mAb). The result showed that the target protein reacted with the anti-his-tag mAb (Fig. 3B) .
Denaturation of inclusion bodies
In the standard protocol, either 6 M guanidine hydrochloride or 8 M urea was used to denature the inclusion bodies. However, in the present study, the recombinant protein vaccine expressed as inclusion body was difficult to dissolve in 6 M guanidine hydrochloride or 8 M urea, even 10 M urea. Thus, higher concentration of guanidine hydrochloride was used. We found that most of inclusion bodies were denatured in 7 M guanidine hydrochloride, and a further increase in concentration did not improve the efficiency further. On the contrary, high concentration of guanidine hydrochloride impaired the ion-exchange chromatography (IEC) and resulted in less efficient renaturation. Unfortunately, almost all of the recombinant protein vaccine that dissolved in 7 M guanidine hydrochloride was precipitated during the refolding process.
To solve this problem, attempts were made to dialyze the denatured proteins into milder condition of 8 M urea, instead of 7 M guanidine hydrochloride. We found that the proteins remained stably dissolved in 8 M urea without precipitation, and this process led to greater renaturation efficiency. The reason might be that the denatured inclusion bodies in 7 M guanidine hydrochloride were gradually refolded to a more stable D r a f t configuration in the milder condition of 8 M urea.
In order to further simplify the denaturation procedures, the inclusion bodies dissolved in 7 M guanidine hydrochloride were gently diluted with 8 M urea until the concentration of guanidine hydrochloride was reduced to 1 M. As a result, not only the inclusion bodies were kept dissolved, possibly with a stable protein conformation in the denaturation conditions, but low concentration of guanidine hydrochloride did not impede the purification process.
Purification and refolding of proteins obtained from inclusion bodies
Ni 2+ affinity chromatography with Ni Sepharose Fast Flow was employed to purify the target protein. Dissolved his-tagged recombinant protein was bound to the Ni 2+ chelated beads. A series of imidazole concentrations (100-500 mM) was used to elute the protein, but no significant differences were found among various concentrations of imidazole. Thus, 500 mM imidazole was used to elute all bound protein for crude purification (Fig. 4) . The results showed that the purity of target proteins was greatly improved. Due to the non-specific adsorption, one-step purification could not be carried out by HisTrap FF column. Therefore, proteins in elution buffer of lanes 6-11
were collected for the further purification.
The proteins collected from HisTrap FF column were well precipitated with 30% saturation (NH 4 ) 2 SO 4 . Then, attempts were made to further purify the proteins using ammonium sulphate fractional precipitation and hydrophobic chromatography methods, both of which failed to improve the purity of proteins. In order to separate the impurities from desired target protein, further purification was carried out by D r a f t ion-exchange chromatography with CM Sepharose Fast Flow.
After precipitation with 30% saturation (NH 4 ) 2 SO 4 and centrifugation, the proteins were redissolved in buffer A to remove imidazole which reduced the efficiency of ion-exchange chromatography. The redissolved proteins were loaded onto the IEC column and eluted with a linear gradient of 0.1-1 M NaCl in buffer A. The results showed that almost all bound proteins were eluted with 100-200 mM NaCl and the purity of target protein was slightly improved to 92%. Thus, proteins with higher purity in lanes 4-8 were collected for further purification (Fig. 5 ).
In general, more stringent requirement is needed for purification of protein with higher purity. Therefore, further purification was performed using Ni-chelating affinity chromatography containing Ni Sepharose High Performance with higher resolution.
Similar to the process of HisTrap FF, the bound proteins were eluted with 100-500 mM imidazole in buffer A. The results showed that most fractions of the recombinant protein vaccine were bound onto HisTrap HP and target proteins with higher purity (more than 95%) were eluted by buffer A containing 100 mM imidazole. Hence, proteins eluted with 100 mM imidazole were collected for renaturation (Fig. 6 ).
Through stepwise dialysis using refolding buffer containing 4, 2, 1 and 0 M urea, the recombinant HIV vaccine was successfully dissolved in PBS. The yield of the refolded recombinant vaccine was approximately 90%, which indicated that folding intermediates were smoothly refolded to a stable protein structure. The purity of the refolded proteins was more than 95% and the yield was 43 mg/L of fermentation medium (Table 1) . After lyophilization with 5% mannitol, the refolded polypeptide D r a f t HIV vaccine was dried to white powder.
Assay of final purity by HPLC
To further quantify the purity of recombinant vaccine, HPLC analysis was used.
The results showed that the retention time of vaccine protein (0.2 g/L) was about 10.006 min and the peak area of vaccine protein accounted for 95.3% (Fig. 7) , indicating the purified vaccine protein reached a purity of 95.3%.
Assay of host protein (HCP) and endotoxin in prepared protein vaccine
According to the corresponding methods described in Chinese pharmacopeia, the residue of HCP and endotoxin were determined as 0.17 ng per mg protein and 0.75 EU per mg protein, respectively. Clearly, the residue of HCP and endotoxin were within the safety range for use in humans. These data further verified the feasibility and reliability of the whole process of purification.
Immunogenicity assay of recombinant vaccine
To test whether the purified protein vaccine remain functional, we used it to immunize mice. ELISpot assay results showed that 4 epitopes within the vaccine (Pol892, Gag297t, Gag297s, and Gag272) stimulated significant T cell responses in male mice (Fig. 8A) . In female mice, not only the same 4 epitopes, but also Gag67 stimulate appreciable T cell response as detected by INFgamma secretion (Fig. 8B ).
These results demonstrate that protein vaccine purified through the above described process retained antigenicity and immunogenicity.
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Conclusions
This paper shows different solubilization conditions of the recombinant protein HIV vaccine expressed as inclusion bodies in E. coli, and a three-step purification process under denaturing conditions followed by stepwise dialysis for renaturation.
Furthermore, protein vaccine that went through these processes remained antigenic and immunogenic.
Our results demonstrate that the proteins extracted from dissolved inclusion bodies maintain a more stable structure in 8 M urea after being treated with a harsher condition of 7 M guanidine hydrochloride, and this milder denaturing condition might have contributed to the more efficient refolding of the recombinant protein HIV vaccine. After sequential purification by HisTrap FF, CM FF and HisTrap HP, the recombinant protein HIV vaccine has reached a purity of 95%, with a total protein recovery rate of 13%. Moreover, the purified protein product retains its desire functional protein as an immungen. The high purity and high yield are amenable to large scale production, and the products generated by our described methods will facilitate the experimental testing of this candidate polypeptide HIV vaccine and enable the development of a CD4+ T cell vaccine especially catered for Chinese. Table   Table 1 Enrichment of HIV vaccine fusion protein after each step of the purification procedure. 166x185mm (300 x 300 DPI)
